Home

Mesoblast (ASX:MSB) - Webinar Presentation

PUBLISHED

2024-03-08

Content

Silviu Itescu - CEO - Mesoblast (ASX:MSB) is using its proprietary mesenchymal lineage cell technology platform to develop and commercialise innovative allogeneic cellular medicines to treat complex inflammatory diseases resistant to conventional standard of care.

Author